Chymopapain

A proteolytic enzyme derived from the papaya plant previously used by intradiscal injection for chemonucleolysis, a non-surgical treatment for herniated lumbar intervertebral discs. It works by dissolving the proteoglycan component of the nucleus pulposus, relieving disc pressure on the nerve. It was withdrawn from the US market due to serious allergic reactions including anaphylaxis and rare neurological complications.

Yes, Chymopapain is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.